Magnesium Cancer Research Results

Magnesium — Magnesium (Mg²⁺; Mg) is an essential divalent mineral cation and obligatory cofactor for hundreds of enzymatic reactions, particularly reactions involving Mg-ATP, nucleic-acid synthesis, ion transport, membrane excitability, and cellular energy metabolism. It is formally classified as an essential mineral/electrolyte rather than an anticancer drug. Dietary magnesium is supplied by leafy vegetables, nuts, seeds, legumes, and whole grains; supplements commonly use citrate, glycinate, chloride, oxide, and other magnesium salts. Magnesium is tightly homeostatically regulated, and its effects differ substantially between correction of deficiency, physiologic sufficiency, manipulation of intracellular Mg²⁺/TRPM7 signaling, and high local concentrations produced experimentally or by degradable magnesium biomaterials.

Primary mechanisms (ranked):

1. Mg-ATP formation and enzymatic support — Mg²⁺ complexes with ATP and is required for kinase activity, glycolysis, oxidative phosphorylation, DNA/RNA synthesis, and numerous metabolic enzymes; this is physiologically essential but is not selectively anticancer and can also support tumor-cell metabolism.
2. TRPM7-mediated Mg²⁺ homeostasis and ion signaling — TRPM7 integrates Mg²⁺, Ca²⁺, Zn²⁺, kinase signaling, proliferation, migration, autophagy, and cell survival. TRPM7 is frequently dysregulated in cancer, but the direction of effect depends on tumor type and whether the channel is inhibited, activated, or exposed to altered intracellular Mg²⁺.
3. Ca²⁺ antagonism and membrane stabilization — adequate Mg²⁺ restrains excessive Ca²⁺ influx and Ca²⁺-dependent signaling and helps stabilize membrane potential and neuromuscular function.
4. DNA synthesis, DNA repair, and genomic stability — Mg²⁺ is required by DNA polymerases and other enzymes involved in nucleic-acid metabolism; deficiency can increase genomic instability, but restoring Mg²⁺ does not selectively damage cancer DNA.
5. Inflammatory and oxidative-stress regulation — magnesium deficiency promotes inflammatory signaling and oxidative stress; correction generally decreases inflammatory/oxidative stress rather than functioning as a tumor-selective ROS generator.
6. High-local or experimentally elevated intracellular Mg²⁺ effects — selected cancer models show increased ROS, ER stress, altered ATP metabolism, autophagy disruption, cell-cycle arrest, or apoptosis when Mg²⁺ homeostasis is strongly perturbed. These findings should not be extrapolated directly to ordinary dietary supplementation.
7. Colorectal cancer prevention biology — human randomized data indicate that magnesium supplementation can modify TRPM7-genotype-dependent gut microbial populations and vitamin-D-related biology associated experimentally with colorectal carcinogenesis, but clinical cancer prevention has not been established.

Bioavailability / PK relevance: Oral absorption is incomplete and homeostatically regulated; approximately 30–40% of dietary magnesium is typically absorbed. More soluble salts such as citrate, chloride, lactate, and aspartate generally show greater gastrointestinal absorption than poorly soluble magnesium oxide, although comparative studies are not completely uniform. Serum Mg²⁺ is tightly maintained at approximately 0.75–0.95 mmol/L and represents less than 1% of total-body magnesium, making serum concentration an imperfect measure of whole-body or intracellular magnesium status. Renal excretion is the principal regulator of systemic magnesium balance.

In-vitro vs systemic exposure relevance: Many cancer experiments involving increased extracellular Mg²⁺, intracellular Mg²⁺ manipulation, TRPM7 pharmacology, or degradable magnesium materials do not represent the exposure produced by routine oral supplementation. Physiologic oral supplementation primarily corrects deficiency and produces relatively small changes in systemic Mg²⁺ because renal and intestinal homeostasis restrict large increases. Consequently, ROS induction, apoptosis, and tumor suppression observed under specialized experimental conditions should be labeled context-dependent rather than treated as general effects of oral magnesium.

Clinical evidence status: Established clinical use is nutritional/electrolyte replacement and treatment or prevention of magnesium deficiency, including hypomagnesemia caused by platinum chemotherapy or EGFR-targeted therapy. Cancer evidence consists mainly of observational associations, mechanistic/preclinical studies, supportive-care trials, and emerging prevention-biomarker RCTs. Magnesium supplementation is not an established anticancer treatment, cytotoxic therapy, radiosensitizer, or chemosensitizer. Excess supplemental magnesium commonly causes gastrointestinal effects; clinically important hypermagnesemia is mainly a concern with very high exposure or impaired renal function.

Magnesium Cancer-Relevant Mechanisms

Magnesium and Alzheimer’s disease: Alzheimer’s-related evidence is strongest for magnesium L-threonate (MgT), a magnesium formulation developed to increase brain magnesium exposure. APP/PS1 mouse studies report improved cognition, synaptic preservation, reduced inflammatory and oxidative-stress signaling, and effects on amyloid-associated pathways. More recent work also implicates hippocampal neurogenesis and the microbiota-gut-brain axis. Human randomized trials of MgT have reported cognitive effects in healthy adults and older adults with cognitive impairment, but MgT has not been demonstrated to treat or modify established Alzheimer’s disease in a definitive AD clinical trial.

Clinical translation: The AD entry should therefore be classified as substantial preclinical evidence with limited indirect human cognitive evidence rather than established Alzheimer’s therapy.

Magnesium Alzheimer’s-Relevant Mechanisms